Xin Lang Cai Jing·2026-03-27 06:53Core Viewpoint - Tiger Med has experienced a 5% increase in stock price, reaching 53.32 CNY per share, with a total market capitalization of 45.91 billion CNY, and a cumulative increase of 6.82% over the past three days [1][5]. Company Overview - Tiger Med, established on December 15, 2004, and listed on August 17, 2012, is located in Hangzhou, Zhejiang Province. The company specializes in providing professional clinical research services for domestic and international pharmaceutical and health-related products [1][5]. - The main business activities include I-IV phase clinical trial technical services, data management and statistical analysis, registration application, on-site clinical trial services, SMO services, medical testing services, medical documentation translation, medical imaging diagnosis services, and training services [1][5]. - The revenue composition of the main business is as follows: clinical trial-related services and laboratory services account for 52.60%, clinical trial technical services for 45.21%, and other services for 2.19% [1][5]. Fund Holdings - Seven funds under Xingyin Fund hold a total of 254,400 shares of Tiger Med, with a floating profit of approximately 646,200 CNY based on the stock price increase [2][6]. - The top funds holding Tiger Med shares include: - Xingyin Smart Consumer Mixed Fund A (018990) holds 52,600 shares, representing 2.99% of the fund's net value, with a floating profit of about 133,600 CNY [3][7]. - Xingyin Stable Return Mixed Fund A (009205) holds 52,000 shares, representing 0.91% of the fund's net value, with a floating profit of about 132,100 CNY [4][8]. - Xingyin Prosperity Preferred Mixed Fund A (010124) holds 45,700 shares, representing 2.46% of the fund's net value, with a floating profit of about 116,100 CNY [4][8].